[Principles of Neoadjuvant Therapy]

Overview

Journal Chirurg

Specialty General Surgery

Date 2009 Oct 9

PMID 19812908

Citations 1

Authors

F Lordick

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant therapy is now an integral part in the treatment of locally advanced cancer of the esophagus and stomach. The mechanisms of action comprise downsizing of the primary tumor, improvement of the T and N categories and the earliest possible eradication of micrometastases. Several controlled clinical studies could show that these principles can indeed augment the rate of curative (R0) resections and can reduce the likelihood of systemic recurrences. As a consequence overall survival is improved by neoadjuvant therapy. This article summarizes how the basic principles of neoadjuvant therapy translate into clinical practice and gives a review of current developmental perspectives in this field.

Citing Articles

Changes in Oncological Surgical Principles Driven by Advances in Preoperative Treatments.

Horvath O, Bellyei S, Pozsgai E, Vereczkei A Ther Clin Risk Manag. 2023; 19:667-674.

PMID: 37575686 PMC: 10422972. DOI: 10.2147/TCRM.S415860.

References

Becker K, Mueller J, Schulmacher C, Ott K, Fink U, Busch R . Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003; 98(7):1521-30. DOI: 10.1002/cncr.11660. View

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T . Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007; 25(10):1160-8. DOI: 10.1200/JCO.2005.04.7118. View

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53(7):925-30. PMC: 1774092. DOI: 10.1136/gut.2003.025080. View

Stahl A, Ott K, Weber W, Becker K, Link T, Siewert J . FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30(2):288-95. DOI: 10.1007/s00259-002-1029-5. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Ribi K, Koeberle D, Schuller J, Honegger H, Roth A, Hess V . Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Support Care Cancer. 2009; 17(8):1109-16. DOI: 10.1007/s00520-008-0570-6. View

Wilke H, Preusser P, Fink U, Achterrath W, Mayer H, Stahl M . New developments in the treatment of gastric carcinoma. Cancer Treat Res. 1991; 55:363-73. DOI: 10.1007/978-1-4615-3882-0_21. View

Siewert J, Lordick F . [Response prediction--early response evaluation. Consequences for surgical oncology]. Chirurg. 2006; 77(12):1095-103. DOI: 10.1007/s00104-006-1270-8. View

10.

Meining A, Dittler H, Wolf A, Lorenz R, Schusdziarra V, Siewert J . You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut. 2002; 50(5):599-603. PMC: 1773190. DOI: 10.1136/gut.50.5.599. View

11.

Feussner H, Hartl F . [Staging laparoscopy in oncology]. Chirurg. 2006; 77(11):971-80. DOI: 10.1007/s00104-006-1259-3. View

12.

Shah M, Ramanathan R, Ilson D, Levnor A, DAdamo D, OReilly E . Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006; 24(33):5201-6. DOI: 10.1200/JCO.2006.08.0887. View

13.

Weber W, Ott K, Becker K, Dittler H, Helmberger H, Avril N . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19(12):3058-65. DOI: 10.1200/JCO.2001.19.12.3058. View

14.

Mandard A, Dalibard F, MANDARD J, Marnay J, Henry-Amar M, Petiot J . Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73(11):2680-6. DOI: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c. View

15.

Lorenzen S, Schuster T, Porschen R, Al-Batran S, Hofheinz R, Thuss-Patience P . Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009; 20(10):1667-73. DOI: 10.1093/annonc/mdp069. View

16.

Lordick F, Ott K, Novotny A, Schuhmacher C, Siewert J . [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. Chirurg. 2007; 78(9):792-801. DOI: 10.1007/s00104-007-1381-x. View

17.

Stahl M, Wilke H, Stuschke M, Walz M, Fink U, Molls M . Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol. 2004; 131(1):67-72. DOI: 10.1007/s00432-004-0604-5. View

18.

Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

19.

Wieder H, Beer A, Lordick F, Ott K, Fischer M, Rummeny E . Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005; 46(12):2029-34. View

20.

Lordick F, Ruers T, Aust D, Collette L, Downey R, El Hajjam M . European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer. 2008; 44(13):1807-19. DOI: 10.1016/j.ejca.2008.06.005. View